The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC (Nasdaq: GMAB) announced today that it has filed its Annual Report for the ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

Agenus Inc. , a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that ...

Nashville-born, North Carolina-bred Dr. James Crowe, Jr. was a curious kid. His appetite for reading was insatiable-which was evident in his weekly ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...